ClinicalTrials.gg
SuspendedNCT04520412GREEN MEMORYUpdated Nov 23, 2022

A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

A Phase 3 interventional study of GV-971 and Placebo in Alzheimer Disease, sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd.. Suspended at 171 sites in 10 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-11-23.

Sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd. · Phase 3, Interventional, and Treatment

Why this study was suspended
The quality of study was seriously affected by the COVID-19, so it was decided to suspend the trial and restart it at the right time.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,046
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
32nd of 1,609
2,046 · median 73
Started
2020
with 103 others
Phase 3
188 of 1,940
19 open now
Registered
1,230th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 32nd largest by planned enrollment of the 1,609 interventional ones that give a count, is one of 104 that started in 2020, is one of 188 in phase 3, and was the 1,230th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of GV-971 in mild to moderate Alzheimer's disease.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild to moderate AD per NIA-AA.
  • History of cognitive and functional decline over at least 1 year.
  • scores between 11 and 24 (inclusive) at baseline.
  • Brain MRI scan show the highest possibility of AD.
  • Have a study partner/caregiver.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a dementia-related central nervous system disease other than AD.
  • Major structural brain disease as judged by MRI.
  • A resting heart rate of \< 50 beats per minute (bpm) after 5 minutes of rest in sitting or supine position.
  • Major medical illness or unstable medical condition within 6 months of screening.
  • Concomitant use of AChEIs and/or memantine within 30 days before first score, and during the study.
  • Inadequate hepatic function.
  • Inadequate organ and marrow function.
  • abnormalities.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,046 participants (estimated)

Study arms

  • Experimental
    GV-971

    Drug: GV-971

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugGV-971

    Administered PO

  • DrugPlacebo

    Administered PO

06

What researchers measure

Primary outcomes

  1. Change from baseline in the ADAS-cog/11 score

    Change from baseline in Alzheimer's Disease Assessments Scale - cognitive (ADAS-cog/11) scale total score. The total score of ADAS-cog/11 is 0-70, with higher scores mean a worse outcome.

    Time frame: Baseline, 48 weeks and 52 weeks

  2. Change from baseline in the ADCS-CGIC score

    Change from baseline on Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) scale total score. The total score of ADCS-CGIC is 1-7, with higher scores mean a worse outcome.

    Time frame: Baseline, 48 weeks and 52 weeks

Secondary outcomes

  1. Change from baseline in NPI score

    Change from baseline in Neuropsychiatric Inventory (NPI) score. The total score of NPI is 0-144, with higher scores mean a worse outcome.

    Time frame: Baseline, 36 Weeks, 52 Weeks

  2. Change from baseline in MMSE score

    Change from baseline in Mini Mental State Examination (MMSE) score. The total score of MMSE is 0-30, with higher scores mean a better outcome.

    Time frame: Baseline, 52 Weeks

  3. Change from baseline in ADCS-ADL23 score

    Change from baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living; 23-item Scale (ADCS-ADL23) score. The total score of ADCS-ADL23 is 0-78, with higher scores mean a better outcome.

    Time frame: Baseline, 36 Weeks, 52 Weeks

  4. Change from baseline in NPI caregiver items

    Change from baseline in Neuropsychiatric Inventory (NPI) caregiver items . The total score of NPI caregiver items is 0-60, with higher scores mean a worse outcome.

    Time frame: Baseline, 52 Weeks

  5. Change from baseline in ZBI score

    Change from baseline in Zarit Burden Interview (ZBI) score. The total score of ZBI is 0-88, with higher scores mean a worse outcome.

    Time frame: Baseline, 52 Weeks

  6. Assess the efficacy of GV-971 throughout the OLE period

    Change from baseline in Alzheimer's Disease Assessments Scale - cognitive (ADAS-cog/11) scale total score. The total score of ADAS-cog/11 is 0-70, with higher scores mean a worse outcome.

    Time frame: Baseline, 52 Weeks, 78 Weeks

  7. Assess the efficacy of GV-971 throughout the OLE period

    Change from baseline on Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) scale total score. The total score of ADCS-CGIC is 1-7, with higher scores mean a worse outcome.

    Time frame: Baseline, 52 Weeks, 78 Weeks

Other outcomes

  1. Evaluate the population PK

    Determine serum levels of GV-971 in population PK

    Time frame: Baseline, 12 Weeks, 24 Weeks, 52 Weeks

  2. Evaluate the effect of GV-971 on brain structure neurodegeneration

    Changes from baseline in volumetric magnetic resonance imaging (MRI)

    Time frame: Baseline, 52 Weeks

07

Study locations

171 sites
  • Cognitive Clinical Trials, LLC
    Gilbert, Arizona 85297, United States
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
  • St. Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • Banner Sun Health Research Institute
    Sun City, Arizona 85351, United States
  • Banner Alzheimer's Institute
    Tucson, Arizona 85718, United States
  • Irvine Clinical Research
    Irvine, California 92614, United States
  • Sunwise Clinical Research
    Lafayette, California 94549, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • Pacific Research Network, Inc
    San Diego, California 92103, United States
  • Pacific Research Network
    San Diego, California 92103, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Schuster Med Research Institute
    Sherman Oaks, California 91403, United States
  • JEM Research LLC
    Atlantis, Florida 33462, United States
  • Brain Matters Research
    Delray Beach, Florida 33445, United States
  • Finlay Medical Research Corp
    Greenacres City, Florida 33467, United States
  • Velocity Clinical Research
    Hallandale Beach, Florida 33009, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Charter Research, LLC
    Lady Lake, Florida 32159, United States
  • Innovative Clinical Research, Inc.
    Lauderhill, Florida 33319, United States
  • ClinCloud, LLC
    Maitland, Florida 32751, United States
  • Merritt Island Medical Research, LLC
    Merritt Island, Florida 32952, United States
  • Collier Neurologic Specialists
    Naples, Florida 34105, United States
  • Suncoast Clinical Research Inc.
    New Port Richey, Florida 34652, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Synexus Clinical Research
    Orlando, Florida 32806, United States
  • Neurology Associates of Ormond Beach
    Ormond Beach, Florida 32174, United States
  • Quantum Lab CNS Clinical Research
    Pompano Beach, Florida 33064, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Intercoastal Medical Group
    Sarasota, Florida 34239, United States
  • Stedman Clinical Trials, LLC
    Tampa, Florida 33613, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Synexus The Villages
    The Villages, Florida 32162, United States
  • NeuroStudies.net, LLC
    Decatur, Georgia 30033, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Alliance Multispecialty Research
    Wichita, Kansas 67207, United States
  • Activmed Practices&Research
    Lawrence, Massachusetts 01843, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • Barnes-Jewish Hospital IDS
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center-Hematology/Oncology Section
    Omaha, Nebraska 68106, United States
  • Cognitive Clinical Trials, LLC
    Omaha, Nebraska 68130, United States
  • Altea Research Institute, Las Vegas
    Las Vegas, Nevada 89102, United States
  • Global Medical Institutes, LLC
    Princeton, New Jersey 08540, United States
  • The Cognitive Research Center of New Jersey
    Springfield, New Jersey 07081, United States
  • Advanced Memory Research Institute of NJ, PC
    Toms River, New Jersey 08755, United States
  • Integrative Clinical Trials LLC
    Brooklyn, New York 11229, United States
  • UBMD Neurology
    Buffalo, New York 14203, United States
  • Clarity Clinical Research
    East Syracuse, New York 13057, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Behavioral Health Research Center
    Charlotte, North Carolina 28211, United States
  • AMC Research, LLC
    Charlotte, North Carolina 28270, United States
  • Guilford Neurologic Associate
    Greensboro, North Carolina 27405, United States
  • Insight Clinical Trials LLC
    Beachwood, Ohio 44122, United States
  • New Horizons Clinical Research
    Cincinnati, Ohio 45040, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Columbus Neuroscience, LLC
    Westerville, Ohio 43082, United States
  • Summit Research Network(Oregon)Inc.
    Portland, Oregon 97210, United States
  • Oregon Health&Science Universty
    Portland, Oregon 97239, United States
  • Oregon Neurology Associates
    Springfield, Oregon 97477, United States
  • Abington Neurological Associates, LTD
    Abington, Pennsylvania 19001, United States
  • SCarolina Institute Brain Health
    Charleston, South Carolina 29401, United States
  • Kerwin Research Center
    Dallas, Texas 75231, United States
  • Huston Methodist Hospital
    Houston, Texas 77030, United States
  • Clinical Trials of Texas; Inc
    San Antonio, Texas 78229, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • Cognition Health
    Fairfax, Virginia 22031, United States
  • University Washington MedCentre
    Seattle, Washington 98104-2499, United States
  • Hornsby Ku-ring-gai Hospital
    Hornsby, New South Wales 2077, Australia
  • KaRa MINDS
    Macquarie Park, New South Wales 2113, Australia
  • Austin Health - Heidelberg Repatriation Hospital
    Melbourne, Victoria 3081, Australia
  • Alzheimer's Research Foundation
    Nedlands, Western Australia 6009, Australia
  • Heritage Medical Research Clinic
    Calgary, Alberta T2N 4Z6, Canada
  • The Medical Arts Health Research Group
    Kamloops, British Columbia V2C 5T1, Canada
  • Okanagan Clinical Trials
    Kelowna, British Columbia V1Y 1Z9, Canada
  • MedicalArtsHealth Research Grp
    Kelowna, British Columbia V1Y 4N7, Canada
  • MedicalArtsHealth Research Grp
    Penticton, British Columbia V2A 5L5, Canada
  • Vancouver Island Health Authority
    Victoria, British Columbia V8R1J8, Canada
  • Medical Arts Health Research Grp
    West Vancouver, British Columbia V7T 1C5, Canada
  • True North Clinical Research Inc
    Halifax, Nova Scotia B3M 1N2, Canada
  • True North Clinical Research
    New Minas, Nova Scotia B4N 3R7, Canada
  • Recherches Neuro-Hippocampe Inc., d/b/a Ottawa Memory Clinic
    Ottawa, Ontario K1Z 1G3, Canada
  • Toronto Memory Program
    Toronto, Ontario M3B 2S7, Canada
  • Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • Clinique Memoire Outaouais
    Gatineau, Quebec J8T 8J1, Canada
  • Q & T Research Sherbrooke Inc
    Sherbrooke, Quebec J1J 2G2, Canada
  • Diex Recherche Sherbrooke
    Sherbrooke, Quebec J1L0H8, Canada
  • Douglas Hospital Research Centre
    Verdun, Quebec H4H 1R3, Canada
  • ALPHA Recherche Clinique
    Quebec, Qc G3K 2P8, Canada
  • 1st Hospital of Anhui MU
    Hefei, Anhui 230022, China
  • Peking Union Hospital
    Beijing, Beijing 100032, China
  • Peking University 1st Hospital
    Beijing, Beijing 100034, China
  • Xuanwu Hospital
    Beijing, Beijing 100053, China
  • Beijing Tiantan Hospital
    Beijing, Beijing 100070, China
  • Beijing Anding Hospital
    Beijing, Beijing 100088, China
  • Beijing Hospital
    Beijing, Beijing 100730, China
  • Beijing Tong Ren Hospital
    Beijing, Beijing 100730, China
  • 1st Hospital of Chongqing MU
    Chongqing, Chongqing 400016, China
  • Fujian Union Hospital
    Fuzhou, Fujian 350001, China
  • 1st Hospital of Fujian MU
    Fuzhou, Fujian 350005, China
  • Zhongshan Hospital Xiamen U
    Xiamen, Fujian 361004, China

Showing the first 100 of 171 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2020 (actual). Primary completion is estimated for Dec 2025, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 20, 2020
StartActual
Oct 27, 2020
Primary completionEst.
Dec 2025
CompletionEst.
Oct 2026
Last update
Nov 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04520412
Lead sponsor
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Aug 20, 2020
Start date
Oct 27, 2020
Primary completion
Dec 2025 (estimated)
Completion
Oct 2026 (estimated)
Last update
Nov 23, 2022

Study contacts

Study Director, Ph D
study director · Green Valley (Shanghai) Pharmaceuticals Co., Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GV-971

Start the discussion